Webcasts Investor Day Meeting Today
VALLEY FORGE, Pa., Dec 16, 2010 (BUSINESS WIRE) --
AmerisourceBergen Corporation (NYSE: ABC) today will reaffirm its
previous fiscal year 2011 guidance at its Investor Day Meeting in New
York City. The Company is hosting a webcast of the meeting today
beginning at 12:30 pm Eastern Standard Time.
The Company continues to expect diluted earnings per share for fiscal
year 2011 to be in a range of $2.31 to $2.41, an increase of 7 percent
to 12 percent over $2.16 per share, which represents the $2.22 diluted
earnings per share achieved in fiscal year 2010 less litigation gains.
Also unchanged are our key assumptions supporting the diluted earnings
per share range for fiscal year 2011, including: revenue growth of
between 2 percent and 4 percent; operating margin growth in the low to
mid single-digit basis points range; and free cash flow in the range of
$625 million to $700 million, which includes capital expenditures in the
$150 million range. Subject to market conditions, we expect to spend
approximately $400 million to repurchase our common shares in fiscal
year 2011.
AmerisourceBergen will webcast its Investor Day Meeting today beginning
at 12:30 pm Eastern Standard Time through approximately 3:30 pm.
Participating in the meeting will be: R. David Yost, Chief Executive
Officer; Steven H. Collis, President and Chief Operating Officer;
Michael D. DiCandilo, Executive Vice President and Chief Financial
Officer; James D. Frary, President, AmerisourceBergen Specialty
Distribution and Services; Peyton R. Howell, President,
AmerisourceBergen Consulting Services; and Antonio R. Pera, Senior Vice
President, Supply Chain Management. To access the live webcast, go to
the Webcasts section on the Investor Relations page at www.amerisourcebergen.com.
A replay of the webcast will be available for 30 days.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With $78 billion in annual revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs
approximately 10,000 people. AmerisourceBergen is ranked #24 on the
Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; quitam litigation for alleged violations of
fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale and purchase of pharmaceutical
products or any related litigation, including shareholder derivative
lawsuits; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; greater or less
than anticipated benefit from launches of the generic versions of
previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to
implement an enterprise resource planning (ERP) system to handle
business and financial processes and transactions (including processes
and transactions relating to our customers and suppliers) of
AmerisourceBergen Drug Corporation and our corporate operations without
functional problems, unanticipated delays and/or cost overruns; success
of integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States, including potential changes
in Canadian provincial legislation affecting pharmaceutical product
pricing or service fees and/or regulatory action by provincial
authorities in Canada to lower pharmaceutical product pricing or service
fees; the impact of divestitures or the acquisition of businesses that
do not perform as we expect, are difficult for us to integrate into our
business operations or do not adhere to our system of internal controls;
our inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax legislation or adverse
resolution of challenges to our tax positions; increased costs of
maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company's Annual Report on Form 10-K for the
Fiscal Year Ended September 30, 2010 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.
SOURCE: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Barbara A. Brungess, 610-727-7199
bbrungess@amerisourcebergen.com